Although some systematic reviews (10, 11) have investigated the demographic and clinical characteristics of EGPA patients, previous studies (12, 13) on biological therapies directed against the IL-5 pathway have not considered all available molecules together but have analyzed them individually or have focused on specific combination of treatments. Here, IL5 is linked to eosinophilic granulomatosis with polyangiitis.